A peptide conjugated with a light-activated dye successfully targeted PD-L1-expressing cancer cells and suppressed tumor growth in mice when activated by near-infrared light.
Significant tumor suppression + extended survivalThe peptide-based photoimmunotherapy drug reduced tumor growth and improved survival in PD-L1-positive mouse models
What the researchers found
The WL12 peptide conjugated with the photoabsorber IR700 (WL12-IR700) successfully induced cancer cell death when activated by near-infrared light. Cell killing was both light dose-dependent and drug concentration-dependent, confirming the dual-trigger mechanism. In PD-L1-positive cell cultures, NIR-PIT with WL12-IR700 caused characteristic morphological changes associated with photoimmunotherapy-mediated cell death. In mouse xenograft models, the treatment significantly suppressed tumor growth and extended overall survival compared to controls.
Why it matters
Current photoimmunotherapy uses antibody-based drugs, which are expensive and slow to develop. Peptides are much smaller, cheaper to produce, and faster to develop. This study shows a peptide can serve the same targeting role as an antibody in photoimmunotherapy, potentially making this promising cancer treatment more accessible and enabling targeting of additional cancer markers.
How the study worked
Researchers conjugated the PD-L1-binding peptide WL12 with the photoabsorber IRDye700DX (IR700). In vitro evaluation used PD-L1-positive cancer cell lines to assess cell viability and morphological changes after NIR light exposure. In vivo experiments used xenograft mouse models to measure tumor growth suppression and overall survival after treatment with WL12-IR700 combined with near-infrared light irradiation.
What this study cannot tell us
This is early-stage preclinical research using cell lines and mouse xenograft models. The specific tumor suppression percentages and survival data were not detailed in the abstract. Near-infrared light has limited tissue penetration, restricting this approach to surface-accessible tumors without specialized light delivery. No toxicity or pharmacokinetic data were reported. Clinical translation would require extensive safety testing.
How to read the evidence
This is a preclinical proof-of-concept study demonstrating feasibility in cell culture and mouse models. While results are promising, it represents the earliest stage of drug development.
When this study was published
Published in 2026, this represents cutting-edge research in peptide-based cancer therapeutics and photoimmunotherapy, an actively developing field.
The bigger picture
Photoimmunotherapy is one of the most exciting emerging cancer treatments — it selectively kills cancer cells while sparing healthy tissue. Currently limited to one antibody-based drug, the field needs cheaper, more versatile alternatives. Peptide-based versions like this could democratize the technology and enable targeting of the many cancers that overexpress PD-L1.
Questions still open
- Could this peptide-based photoimmunotherapy approach be combined with PD-1/PD-L1 checkpoint inhibitor antibodies for enhanced anti-tumor effects?
- What types of cancer would be most accessible to this NIR light-activated treatment in clinical practice?
- How does the tumor penetration of this small peptide conjugate compare to the larger antibody-based photoimmunotherapy drugs?
Common questions
What is photoimmunotherapy and how does a peptide version work?
Why use a peptide instead of an antibody for cancer treatment?
Read the original research
Development of a Peptide-Based Photoimmunotherapy Drug Targeting PD-L1.
Molecules (Basel, Switzerland), 31(2)
Citation
Otani, Takuya; Kondo, Naoya; Kanai, Ayaka; Hanaoka, Hirofumi. (2026). Development of a Peptide-Based Photoimmunotherapy Drug Targeting PD-L1.. Molecules (Basel, Switzerland), 31(2). https://doi.org/10.3390/molecules31020302